These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35644340)

  • 1. Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Nguyen NH; Luo J; Paul P; Kim J; Syal G; Ha C; Rudrapatna V; Park S; Parekh N; Zheng K; Sauk JS; Limketkai B; Fleshner P; Eisenstein S; Ramamoorthy S; Melmed G; Dulai PS; Boland BS; Mahadevan U; Sandborn WJ; Ohno-Machado L; McGovern D; Singh S
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):173-181.e5. PubMed ID: 35644340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
    Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
    Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Ibing S; Cho JH; Böttinger EP; Ungaro RC
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Sangaralingham L; Shah ND; Sandborn WJ
    Clin Transl Gastroenterol; 2021 Jul; 12(7):e00380. PubMed ID: 34228004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.
    Singh S; Iversen AT; Allin KH; Jess T
    JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Solitano V; Facciorusso A; Jess T; Ma C; Hassan C; Repici A; Jairath V; Armuzzi A; Singh S
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):907-921.e2. PubMed ID: 35944832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Sangaralingham L; Shah ND; Lai JC; Sandborn WJ; Moore AA
    Inflamm Bowel Dis; 2021 Oct; 27(10):1626-1633. PubMed ID: 33325507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
    Kochar B; Pate V; Kappelman MD; Long MD; Ananthakrishnan AN; Chan AT; Sandler RS
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1299-1305.e5. PubMed ID: 34481954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
    Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
    Tepeš K; Hanžel J; Štubljar D; Strmšek K; Erjavec L; Supovec E; Jagodic Z; Končan M; Grosek J; Košir JA; Tomažič A; Kogovšek U; Norčič G; Šibli R; Žnidaršič M; Pačnik Vižintin T; Sodin B; Breznik J; Hribar VA; Ocepek A; Pernat Drobež C; Bukovnik N; Zafošnik A; Marušič T; Jurečič Brglez N; Denkovski M; Smrekar N; Novak G; Koželj M; Kurent T; Simonič J; Pintar Š; Štabuc B; Drobne D
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):728-734. PubMed ID: 38625825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Herrin J; Dulai PS; Sangaralingham L; Shah ND; Sandborn WJ
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e74-e88. PubMed ID: 33640480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study.
    Holmer AK; Luo J; Russ KB; Park S; Yang JY; Ertem F; Dueker J; Nguyen V; Hong S; Zenger C; Axelrad JE; Sofia A; Petrov JC; Al-Bawardy B; Fudman DI; Llano E; Dailey J; Jangi S; Khakoo N; Damas OM; Barnes EL; Scott FI; Ungaro RC; Singh S;
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1598-1606.e5. PubMed ID: 36642291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
    Kochhar GS; Desai A; Farraye FA; Cross RK; El-Hachem S; Dulai PS; Regueiro M
    Aliment Pharmacol Ther; 2023 Aug; 58(3):297-308. PubMed ID: 37300328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
    Cheng D; Kochar B; Cai T; Ritchie CS; Ananthakrishnan AN
    Am J Gastroenterol; 2022 Nov; 117(11):1845-1850. PubMed ID: 35854436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
    Lukin D; Faleck D; Xu R; Zhang Y; Weiss A; Aniwan S; Kadire S; Tran G; Rahal M; Winters A; Chablaney S; Koliani-Pace JL; Meserve J; Campbell JP; Kochhar G; Bohm M; Varma S; Fischer M; Boland B; Singh S; Hirten R; Ungaro R; Lasch K; Shmidt E; Jairath V; Hudesman D; Chang S; Swaminath A; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Siegel CA; Sandborn WJ; Dulai PS
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):126-135. PubMed ID: 33039584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.